BACKGROUND: Targeted therapies improve survival in metastatic @entity1358 (mRCC). However, survival patterns can be divergent, and @entity1 at the 2 extremes of the survival spectrum need to be characterized. @entity1 AND METHODS: Data from 2161 @entity1 included in the International mRCC Database Consortium (IMDC) were analyzed. We identified @entity1 on the basis of their duration of survival. Long-term survival (LTS) was defined as overall survival (OS) of  >=  4 years, and short-term survival (STS) was defined as OS of   <= 6 months from the start of targeted therapy. Baseline characteristics, including demographic, clinicopathologic, and laboratory data, were compared between LTS and STS. Treatment response by the RECIST criteria was summarized for the 2 survival groups. RESULTS: A total of 152 @entity1 experienced LTS and 218 experienced STS. Adverse clinical and laboratory prognostic factors previously described in the IMDC prognostic model were significantly more frequent in the STS  group (P  < .0001). In the LTS group, 138 @entity1 (91%) had @entity66 ( @entity66 ) as best response to first-line targeted therapy, and 56 (60%) of 94 @entity1 who received second-line therapy had @entity66 . In the STS  group, only 51 @entity1 (23%) had @entity66 on first-line therapy. None of 21 the @entity1 who received second-line  therapy had @entity66 as best response. In LTS, the median duration of therapy was 23.6 months (range 0.4 to 81.8+ months) for first-line therapy and 11.5 months (range 0.6 to 45.7 months) for second-line therapy, compared to 2.0 and 0.8 months for the STS group, respectively. CONCLUSION: Baseline prognostic criteria and absence of @entity1726 after first and second-line targeted therapy may characterize long-term survival.

Characteristics of Long-Term and Short-Term Survivors of XXXX Treated With Targeted Therapies: Results From the International mRCC Database Consortium.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity1726 :: ('OMIM:168600', 'Disease') :: ['PD'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma'] @entity66 :: ('MESH:D004194', 'Disease') :: ['nonprogressive disease', 'non-PD']
@entity1358 :: (MESH:D002292,Disease) :: ['Metastatic Renal Cell Carcinoma']
